肿瘤短链脂肪酸代谢PET显像剂研究进展

张占文; 胡平; 唐刚华; 张占文; 胡平; 唐刚华

doi:10.3760/cma.j.issn.1673-4114.2017.06.009

[1]

Currie E, Schulze A, Zechner R, et al. Cellular fatty acid metabolism and cancer[J]. Cell Metab, 2013, 18(2):153-161. DOI:10.1016/j.cmet.2013.05.017.

[2]

Santos CR, Schulze A. Lipid metabolism in cancer[J]. FEBS J, 2012, 279(15):2610-2623. DOI:10.1111/j.1742-4658. 2012.08644.x.

[3]

Gropler RJ. Recent advances in metabolic imaging[J]. J Nucl Cardiol, 2013, 20(6):1147-1172. DOI:10.1007/s12350-013-9786-z.

[4]

孙爱君, 任茜, 刘健, 等. ¹¹C-乙酸盐PET和PET/CT在肿瘤显像中的应用[J].国际放射医学核医学杂志, 2013, 37(4):243-247. DOI:10.3760/cma.j.issn.1673-4114.2013.04.013.
Sun AJ, Ren Q, Liu J, et al. The application of ¹¹C-acetate PET and PET-CT for tumors[J]. Int J Radiat Med Nucl Med, 2013, 37(4):243-247. doi: 10.3760/cma.j.issn.1673-4114.2013.04.013

[5]

Yoshii Y, Furukawa T, Saga T, et al. Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis:overview and application[J]. Cancer Lett, 2015, 356(2 Pt A):211-216. DOI:10.1016/j.canlet.2014.02.019.

[6]

Yoshii Y, Furukawa T, Oyama N, et al. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer:uptake of radiolabeled acetate as a predictor of the targeted therapy outcome[J/OL]. PLoS One, 2013, 8(5):e64570[2017-06-28]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0064570. DOI:10.1371/journal.pone.0064570.

[7]

Zaytseva YY, Elliott VA, Rychahou P, et al. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer[J]. Carcinogenesis, 2014, 35(6):1341-1351. DOI:10.1093/carcin/bgu042.

[8]

Plathow C, Weber WA. Tumor cell metabolism imaging[J]. J Nucl Med, 2008, 49 suppl 2:43S-59S. DOI:10.2967/jnumed.107. 045930.

[9]

Agostini M, Almeida LY, Bastos DC, et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas[J]. Mol Cancer Ther, 2014, 13(3):585-595. DOI:10.1158/1535-7163.MCT-12-1136.

[10]

Seguin F, Carvalho MA, Bastos DC, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas[J]. Br J Cancer, 2012, 107(6):977-987.DOI:10.1038/bjc.2012.355.

[11]

Brown M, Marshall DR, Sobel BE, et al. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate[J]. Circulation, 1987, 76(3):687-696. DOI:10.1161/01.CIR.76.3.687.

[12]

Henes CG, Bergmann SR, Walsh MN, et al. Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate[J]. J Nucl Med, 1989, 30(9):1489-1499.

[13]

Park JW, Kim JH, Kim SK, et al. A prospective evaluation of ¹⁸F-FDG and ¹¹C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12):1912-1921.DOI:10.2967/jnumed.108.055087.

[14]

Huo L, Dang Y, Lv J, et al. Application of dual phase imaging of ¹¹C-acetate positron emission tomography on differential diagnosis of small hepatic lesions[J/OL]. PLoS One, 2014, 9(5):e96517[2016-06-28]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0096517. DOI:10.1371/journal.pone.0096517.

[15]

Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[¹⁸F] fluoro-D-glucose, 6-deoxy-6[¹⁸F]fluoro-D-glucose, [1-¹¹C]-acetate and[N-methyl-¹¹C]-choline[J]. Q J Nucl Med Mol Imaging, 2009, 53(2):144-156.

[16]

Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease[J]. J Nucl Med, 1995, 36(9):1595-1601.

[17]

Oyama N, Okazawa H, Kusukawa N, et al. ¹¹C-Acetate PET imaging for renal cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2009, 36(3):422-427. DOI:10.1007/s00259-008-0981-0.

[18]

霍力, 周前, 吴战宏, 等. ¹¹C-乙酸盐PET显像在肾脏肿瘤诊断中的作用[J].中华核医学杂志, 2006, 26(4):205-208. DOI:10.3760/cma.j.issn.2095-2848. 2006.04.003.
Huo L, Zhou Q, Wu ZH, et al. The role of ¹¹C-acetate PET imaging for diagnosis of renal cancer[J]. Chin J Nucl Med, 2006, 26(4):205-208. doi: 10.3760/cma.j.issn.2095-2848.2006.04.003

[19]

Oyama N, Akino H, Kanamaru H, et al. ¹¹C-acetate PET imaging of prostate cancer[J]. J Nucl Med, 2002, 43(2):181-186.

[20]

Albrecht S, Buchegger F, Soloviev D, et al. ¹¹C-acetate PET in the early evaluation of prostate cancer recurrence[J]. Eur J Nucl Med Mol Imaging, 2007, 34(2):185-196. DOI:10.1007/s00259-006-0163-x.

[21]

Brogsitter C, Zöphel K, Kotzerke J. ¹⁸F-Choline, ¹¹C-choline and ¹¹C-acetate PET/CT:comparative analysis for imaging prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2013, 40 suppl 1:S18-27. DOI:10.1007/s00259-013-2358-2.

[22]

Tang G, Tang X, Wang M, et al. A simple and rapid automated radiosynthesis of[¹⁸F]fluoroacetate[J]. J Labelled Compd Radiopharm, 2008, 51(7):297-301. DOI:10.1002/jlcr.1520.

[23]

Ponde DE, Dence CS, Oyama N, et al. ¹⁸F-fluoroacetate:a potential acetate analog for prostate tumor imaging-in vivo evaluation of ¹⁸F-fluoroacetate versus ¹¹C-acetate[J]. J Nucl Med, 2007, 48(3):420-428.

[24]

Lindhe O, Sun A, Ulin J, et al.[¹⁸F] Fluoroacetate is not a functional analogue of[¹¹C]acetate in normal physiology[J]. Eur J Nucl Med Mol Imaging, 2009, 36:1453-1459. DOI:10.1007/s00259-009-1128-7.

[25]

Matthies A, Ezziddin S, Ulrich EM, et al. Imaging of prostate cancer metastases with ¹⁸F-fluoroacetate using PET/CT[J]. Eur J Nucl Med Mol Imaging, 2004, 31(5):797. DOI:10.1007/s00259-003-1437-1.

[26]

Liu RS, Chou TK, Chang CH, et al. Biodistribution, pharmacokinetics and PET imaging of[¹⁸F]FMISO, [¹⁸F]FDG and[¹⁸F]FAc in a sarcoma-and inflammation-bearing mouse model[J]. Nucl Med Biol, 2009, 36(3):305-312. DOI:10.1016/j.nucmedbio.2008.12.011.

[27]

周硕, 朱庆国, 叶烈夫, 等. ¹⁸F-氟乙酸联合¹⁸F-FDG PET/CT显像在肾肿瘤鉴别诊断中的价值[J].大连医科大学学报, 2016, 38(4):340-343, 360. DOI:10.11724/jdmu.2016.04.06.
Zhou S, Zhu QG, Ye LF, et al. Value of ¹⁸F-flunoroacetate combined with ¹⁸F-fluorodeoxyglucose in differential diagnosis of renal masses[J]. J Dalian Med Univ, 2016, 38(4):340-343, 360. doi: 10.11724/jdmu.2016.04.06

[28]

Takemoto K, Hatano E, Nishii R, et al. Assessment of[¹⁸F]-fluoroacetate PET/CT as a tumor-imaging modality:preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor[J]. Ann Nucl Med, 2014, 28(4):371-380. DOI:10.1007/s12149-014-0823-z.

[29]

Ho CL, Cheung MK, Chen S, et al.[¹⁸F] fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases:an alternative tracer for[¹¹C] acetate?[J]. Mol Imaging, 2012, 11(3):229-239. DOI:10.2310/7290. 2011.00043.

[30]

Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation:acetate metabolism in tumor cells[J]. Nucl Med Biol, 2001, 28(2):117-122. DOI:10.1016/S0969-8051(00)00195-5.

[31]

Pillarsetty N, Punzalan B, Larson SM. 2-¹⁸F-Fluoropropionic acid as a PET imaging agent for prostate cancer[J]. J Nucl Med, 2009, 50(10):1709-1714. DOI:10.2967/jnumed.109.064212.

[32]

党永红, 蔡炯, 王玲, 等. 2-¹⁸F-氟代丙酸的自动化合成及其Micro PET肺癌小鼠显像[J].中国医学装备, 2015, 12(6):46-49. DOI:10.3969/J.ISSN.1672-8270. 2015.06.015.
Dang YH, Cai J, Wang L, et al. The automated synthesis of 2-¹⁸F-fluoropropoinic acid and micro PET imaging in mice of lung cancer[J]. China Med Equip, 2015, 12(6):46-49. doi: 10.3969/J.ISSN.1672-8270.2015.06.015

[33]

Wang HL, Hu KZ, Tang GH, et al. Simple and efficient automated radiosynthesis of 2-¹⁸F-fluoropropionic acid using solid-phase extraction cartridges purification[J]. J Label Compd Radiopharm, 2012, 55(2):366-370. DOI:10.1002/jlcr.2952.

[34]

党永红, 蔡炯, 李欣, 等. 2-¹⁸F-氟丙酸在荷乳腺癌小鼠模型中的显像性能和体内分布[J].中国医学科学院学报, 2015, 37(3):320-324. DOI:10.3881/j.issn.1000-503X.2015.03.014.
Dang YH, Cai J, Li X, et al. Imaging potential and biodistribution in vivo of 2-[¹⁸F] fluoropropionic acid in breast cancer-bearing mice[J]. Acta Academiae Medicinae Sinicae, 2015, 37(3):320-324. doi: 10.3881/j.issn.1000-503X.2015.03.014

[35]

Pisaneschi F, Witney TH, Iddon L, et al. Synthesis of[¹⁸F] fluoro-pivalic acid:an improved PET imaging probe for the fatty acid synthesis pathway in tumours[J]. Med Chem Commun, 2013, 4(10):1350-1353. DOI:10.1039/c3md00169e.

[36]

Witney TH, Pisaneschi F, Alam IS, et al. Preclinical evaluation of 3-¹⁸F-fluoro-2, 2-dimethylpropionic acid as an imaging agent for tumor detection[J]. J Nucl Med, 2014, 55(9):1506-1512. DOI:10.2967/jnumed.114.140343.

[37]

Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man[J]. Pharmacol Rev, 2002, 54(4):589-598. DOI:10.1124/pr.54.4.589.